LEXINGTON, Mass., July 21,
2020 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN),
an immuno-oncology (I-O) company with
a pipeline of immune checkpoint antibodies,
adoptive cell therapies and cancer
vaccines, announced today that Dr. Jennifer Buell, President and COO of Agenus, and
Dr. Manuel Hidalgo, Chief of the
Division of Hematology and Medical Oncology at Weill Cornell
Medicine/New York Presbyterian Hospital, will discuss AgenTus
Therapeutics, Inc.'s (a subsidiary of Agenus) allogeneic iNKT cell
therapy approach for infectious diseases at the B. Riley Virtual
Infectious Disease Summit – Therapeutics Day on a Panel entitled
Pursuing Curative Cell Therapy Approaches.
Date: Tuesday, July 21,
2020
Time: 3:00 PM –
4:00 PM ET
Title: Pursuing Curative Cell Therapy Approaches –
Cell Therapy has become a fast-changing field after becoming a
powerful clinical therapy for late line cancer patients with the
approval of the first generation CD19+ CAR T cell treatments
(Yescarta and Kymriah). Participants in the panel include AgenTus
Therapeutics, a biotech company and subsidiary of Agenus Inc.
developing new cancer treatments, including AGENT-797, an early
unmodified allogeneic iNKTcell therapy, Magenta Therapeutics, a
cell therapy company developing novel cell therapies including
MGTA-456, a stem -cell production therapy, and SQZ Biotechnologies
Company, a biotech company developing oncology drugs including APC
HPV, an autologous based therapy for several types of cancer.
Agenus Inc.
Jennifer
Buell, Ph.D. – President and Chief Operating Officer
Manuel Hidalgo, M.D. –Chief of the
Division of Hematology and Medical Oncology at Weill Cornell
Medicine/New York Presbyterian
Excision BioTherapeutics
Daniel Dornbusch - Chief Executive
Officer
Pluristem Therapeutics (PSTI)
Racheli Ofir – Vice President of Research &
IP
About AgenTus Therapeutics, Inc.
AgenTus
Therapeutics is a biopharmaceutical company focused on the
discovery, development, and commercialization of breakthrough
allogeneic iNKT cells in the unmodified and modified with
engineered receptors, such as T cell receptors (TCRs) and Chimeric
Antigen Receptors (CARs), designed to supercharge the human immune
system cells to seek and destroy cancer. AgenTus also aims to
advance adoptive cell therapy formats which would enable
off-the-shelf living drugs. AgenTus has locations
in Lexington, MA and Cambridge, UK. For more
information, please
visit www.agentustherapeutics.com.
About Agenus
Agenus is a clinical-stage immuno-oncology company focused on the
discovery and development of therapies that engage the body's
immune system to fight cancer and infections. The Company's vision
is to expand the patient populations benefiting from cancer
immunotherapy by pursuing combination approaches that leverage a
broad repertoire of antibody therapeutics, adoptive cell therapies
(through its AgenTus Therapeutics subsidiary), and proprietary
cancer vaccine platforms. The Company is equipped with a suite of
antibody discovery platforms and a state-of-the-art GMP
manufacturing facility with the capacity to support clinical
programs. Agenus is headquartered in Lexington, MA. For more information, please
visit www.agenusbio.com and our Twitter handle @agenus_bio.
Information that may be important to investors will be routinely
posted on our website and twitter.
Contact:
Agenus Inc.
Jennifer
Buell, PhD
781-674-4420
Jennifer.Buell@agenusbio.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/agenus-to-participate-in-a-panel-on-cell-therapy-for-infectious-diseases-at-the-b-riley-virtual-infectious-disease-summit-301097296.html
SOURCE Agenus Inc.